Next-morning impairment leads to lower doses for zolpidem sleep aids
This article was originally published in Scrip
US regulators on 10 January told makers of sedative-hypnotic sleep aids containing zolpidem, such as Sanofi's Ambien, to lower the recommended dose in labeling for women from 10mg to 5mg for immediate-release products and from 12.5mg to 6.25mg for extended-release medicines because of the risk of next-morning impairment.
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.